Category Focus Rewards Biopharma Shareholders
For decades, biopharma companies have relentlessly pursued growth, counting on pure scale and M&A cost synergies to create value. This strategy is reaching its limits and becoming counterproductive, according to Bain & Co. analysis. Megamergers that don’t produce category leaders also don’t create portfolios that are likely to deliver attractive shareholder returns over time.
You may also be interested in...
How Healthy Is Your Growth Strategy? Five Principles To Fight Complexity In Today’s Medtech And Biopharma Enterprise
Top performers in today’s health care market are transforming their growth strategies. They excel at category leadership, cost reduction and customer-focused innovation. Complexity – in strategy, portfolios, operations, organizations and people – is a little-noticed impediment to achieving margin-busting growth, on target and on time.
Datamonitor Healthcare's measurement of pharma R&D return on investment finds that Mid Pharma companies outperform on an ROI index. The second in a two-part series evaluating R&D productivity.
Datamonitor Healthcare's recent review of R&D efficiency using new product launch success rates as a proxy shows that Mid Pharma companies outperform Big Pharma and Japan Pharma firms, thanks to multiple blockbuster drugs. The first in a two-part series evaluating R&D productivity.